Occult hepatitis B virus and hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 20, 2014, Pages 5951-5961

  Pollicino, Teresa ^a   Saitta, Carlo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

HBx protein; Hepatitis B virus; Hepatitis B virus DNA; Hepatitis B virus surface antigen; Hepatocellular carcinoma; Occult hepatitis B virus infection

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HISTONE DEACETYLASE; NICOTINAMIDE; PEPTIDES AND PROTEINS; TRICHOSTATIN A; TRUNCATED PRES S PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VITRONECTIN; VIRUS DNA;

APOPTOSIS; ARTICLE; DNA HYBRIDIZATION; EPIGENETICS; GENE; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HISTONE METHYLATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; META ANALYSIS (TOPIC); MUTATION; PARTITIONING DEFECTIVE 6 HOMOLOG GAMMA GENE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VIRUS REPLICATION; ANIMAL; BLOOD; COMPLICATION; DISEASE COURSE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; INFLAMMATION; LIVER; LIVER CELL; LIVER NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS GENOME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DNA, VIRAL; GENOME, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; LIVER NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84901492681     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i20.5951     Document Type: Article

References (114)

1. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273. [PMID: 18848855 DOI: 10.1016/ j.vaccine.2008.09.056]
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. [PMID: 17570226 DOI: 10.1053/ j.gastro.2007.04.061]
3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34. [PMID: 15508094 DOI: 10.1053/j.gastro.2004.09.013]
4. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044. [PMID: 16404738 DOI: 10.1002/ijc.21731]
5. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133. [PMID: 6118576 DOI: 10.1016/S0140-6736(81)90585-7]
6. Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med 2009; 76 Suppl 3: S6-S9. [PMID: 19465708 DOI: 10.3949/ccjm.76.s3.02]
7. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepato-cellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009; 16: 453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x]
8. Lee CL, Hsieh KS, Ko YC. Trends in the incidence of heap-tocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003; 12: 57-59. [PMID: 12540504]
9. Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009; 181: 85-94. [PMID: 19213561 DOI: 10.1007/978-3-540-69297-3_10]
10. Lee MS, Kim DH, Kim H, Lee HS, Kim CY, Park TS, Yoo KY, Park BJ, Ahn YO. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol 1998; 27: 316-319. [PMID: 9602416 DOI: 10.1093/ije/27.2.316]
11. IARC. Tobacco smoke and involuntary smoking. In: IARC Monograph. Lyon, France: International Agency for Research on Cancer, 2004
12. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574. [PMID: 21497551 DOI: 10.1016/ S1470-2045(11)70077-8]
13. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. [PMID: 16391218 DOI: 10.1001/ jama.295.1.65]
14. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009; 49: S56-S60. [PMID: 19399807 DOI: 10.1002/ hep.22962]
15. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657. [PMID: 18715666 DOI: 10.1016/j.jhep.2008.07.014]
16. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011; 32: 1122-1132. [PMID: 21665892 DOI: 10.1093/carcin/ bgr108]
17. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112. [PMID: 1054319]
18. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298: 1379-1383. [PMID: 652005 DOI: 10.1056/NEJM197806222982502]
19. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26. [PMID: 10387938 DOI: 10.1056/ NEJM199907013410104]
20. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486. [PMID: 12150847 DOI: 10.1016/ S1473-3099(02)00345-6]
21. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013; 35: 39-52. [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7]
22. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013; 59: 696-700. [PMID: 23751755 DOI: 10.1016/j.jhep.2013.05.043]
23. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408. [PMID: 17382608 DOI: 10.1016/ j.dld.2006.12.017]
24. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48: 1001-1026. [PMID: 18454738 DOI: 10.1111/j.1537-2995.2008.01701.x]
25. Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 2010; 16: 1314-1323. [PMID: 21031547 DOI: 10.1002/ lt.22169]
26. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279. [PMID: 20034693 DOI: 10.1016/j.jhep.2009.11.009]
27. Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 2011; 18: 461-466. [PMID: 21912252 DOI: 10.1097/MOH.0b013e32834bac10]
28. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257. [PMID: 12081601 DOI: 10.1046/j.1365-2893.2002.00344.x]
29. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170. [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007]
30. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712. [PMID: 17338776 DOI: 10.1111/j.1365-2141.2006.06465.x]
31. Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol 2011; 17: 1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17. i12.1529]
32. de la Fuente RA, Gutiérrez ML, Garcia-Samaniego J, Fernández-Rodriguez C, Lledó JL, Castellano G. Pathogenesis of occult chronic hepatitis B virus infection. World J Gastroenterol 2011; 17: 1543-1548. [PMID: 21472118 DOI: 10.3748/wjg.v17. i12.1543]
33. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25: 142-163. [PMID: 22232374 DOI: 10.1128/CMR.00018-11]
34. Fernandez-Rodriguez CM, Gutierrez ML, Lledó JL, Casas ML. Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. World J Gastroenterol 2011; 17: 1558-1562. [PMID: 21472121 DOI: 10.3748/wjg.v17.i12.1558]
35. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol 2011; 17: 1563-1568. [PMID: 21472122 DOI: 10.3748/wjg.v17.i12.1563]
36. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008; 134: 235-249. [PMID: 18339439 DOI: 10.1016/j.virusres.2007.12.024]
37. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68. [PMID: 10704474 DOI: 10.1128/ MMBR.64.1.51-68.2000]
38. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13: 48-64. [PMID: 17206754]
39. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; 52: 282-284. [PMID: 20056291 DOI: 10.1016/j.jhep.2009.10.031]
40. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592. [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022]
41. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308. [PMID: 15710212 DOI: 10.1016/j.jhep.2004.12.015]
42. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203. [PMID: 11431751 DOI: 10.1053/jhep.2001.25172]
43. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742. [PMID: 9620351 DOI: 10.1002/ hep.510270638]
44. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
45. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 2007; 13: 5682-5686. [PMID: 17963292]
46. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45: 277-285. [PMID: 17256766 DOI: 10.1002/hep.21529]
47. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108. [PMID: 8837608 DOI: 10.1038/nm1096-1104]
48. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del Prete G, Fiaccadori F, Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-1194. [PMID: 8787682 DOI: 10.1172/JCI118902]
49. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758. [PMID: 15188170 DOI: 10.1053/j.gastro.2004.03.018]
50. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-836. [PMID: 21809355 DOI: 10.1002/hep.24551]
51. Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 2006; 45: 553-559. [PMID: 16904225 DOI: 10.1016/ j.jhep.2006.05.014]
52. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-110. [PMID: 14699492 DOI: 10.1053/ j.gastro.2003.10.048]
53. Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J, Sauleda S. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol 2012; 56: 765-774. [PMID: 22173156 DOI: 10.1016/j.jhep.2011.11.011]
54. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470-1481. [PMID: 18355815 DOI: 10.1053/j.gastro.2008.02.017]
55. Coffin CS, Pham TN, Mulrooney PM, Churchill ND, Michalak TI. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology 2004; 40: 1053-1061. [PMID: 15382154 DOI: 10.1002/hep.20419]
56. Lieberman PM. Chromatin organization and virus gene expression. J Cell Physiol 2008; 216: 295-302. [PMID: 18314879 DOI: 10.1002/jcp.21421]
57. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J. Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 2010; 1799: 228-235. [PMID: 19853674 DOI: 10.1016/ j.bbagrm.2009.10.005]
58. Bloom DC, Giordani NV, Kwiatkowski DL. Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 2010; 1799: 246-256. [PMID: 20045093 DOI: 10.1016/ j.bbagrm.2009.12.001]
59. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837. [PMID: 16530522 DOI: 10.1053/j.gastro.2006.01.001]
60. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009; 94: 1618-1622. [PMID: 19608677 DOI: 10.3324/haematol.2009.008607]
61. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 2007; 356: 1591-1592. [PMID: 17429098 DOI: 10.1056/NEJMc063696]
62. Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. J Infect Dis 2009; 199: 1286-1291. [PMID: 19301974 DOI: 10.1086/597614]
63. Kaur P, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z. DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis 2010; 202: 700-704. [PMID: 20653444 DOI: 10.1086/655398]
64. Ruiz J, Sangro B, Cuende JI, Beloqui O, Riezu-Boj JI, Herrero JI, Prieto J. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology 1992; 16: 637-641. [PMID: 1380480 DOI: 10.1002/hep.1840160305]
65. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981; 305: 1067-1073. [PMID: 6268980 DOI: 10.1056/NEJM198110293051807]
66. Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, Lee PH, Lai MY, Wang CY, Yang PM. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322-1327. [PMID: 1327934]
67. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, Idrovo V, Rabassa A, Schiff ER. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993; 18: 1326-1333. [PMID: 8244256]
68. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, Bréchot C. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 1993; 17: 20-29. [PMID: 8380790 DOI: 10.1002/hep.1840170106]
69. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-321. [PMID: 7843699]
70. Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology 1997; 25: 226-228. [PMID: 8985295 DOI: 10.1002/hep.510250141]
71. Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, Ting LT, Chang FY, Lee SD. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231-236. [PMID: 9657117 DOI: 10.1002/hep.510280130]
72. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998; 54: 249-255. [PMID: 9557290 DOI: 10.1002/(SICI)1096-9071(199804)54]
73. Kubo S, Nishiguchi S, Tamori A, Hirohashi K, Kinoshita H, Kuroki T. Development of hepatocellular carcinoma in patients with HCV infection, with or without past HBV infection, and relationship to age at the time of transfusion. Vox Sang 1998; 74: 129. [PMID: 9501414 DOI: 10.1046/ j.1423-0410.1998.7420129.x]
74. Poussin K, Dienes H, Sirma H, Urban S, Beaugrand M, Franco D, Schirmacher P, Bréchot C, Paterlini Bréchot P. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 1999; 80: 497-505. [PMID: 9935147 DOI: 10.1002/(SICI)1097-0215(19990209)80]
75. Yotsuyanagi H, Hashidume K, Suzuki M, Maeyama S, Takayama T, Uchikoshi T. Role of hepatitis B virus in hepatocarcinogenesis in alcoholics. Alcohol Clin Exp Res 2004; 28: 181S-185S. [PMID: 15318109 DOI: 10.1111/j.1530-0277.2004.tb03240.x]
76. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006; 25: 3756-3770. [PMID: 16799617 DOI: 10.1038/sj.onc.1209557]
77. Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000; 33: 992-997. [PMID: 11131464 DOI: 10.1016/S0168-8278(00)80134-8]
78. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37: 1172-1179. [PMID: 12717399 DOI: 10.1053/jhep.2003.50171]
79. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008; 14: 534-540. [PMID: 18324677 DOI: 10.1002/lt.21284]
80. Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk GD, Thomas DL, Torbenson M. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 2007; 39: 101-105. [PMID: 17452002 DOI: 10.1016/ j.jcv.2007.03.006]
81. Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 2009; 51: 824-825. [PMID: 19664841 DOI: 10.1016/j.jhep.2009.06.007]
82. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet 2005; 365: 638-640. [PMID: 15721459 DOI: 10.1016/ S0140-6736(05)70913-2]
83. Koike K, Shimotouno K, Okada S, Okamoto H, Hayashi N, Ueda K, Kaneko S, Koike K, Yokosuka O, Chiba T, Marusawa H, Hino O, Utida T, Omata M, Juji T, Nojiri N, Takada K, Miyamura T, Osuga T, Ito Y. Survey of hepatitis B virus coinfection in hepatitis C virus-infected patients suffering from chronic hepatitis and hepatocellular carcinoma in Japan. Jpn J Cancer Res 1999; 90: 1270-1272. [PMID: 10622540 DOI: 10.1111/j.1349-7006.1999.tb00707.x]
84. Chang ML, Lin YJ, Chang CJ, Yeh C, Chen TC, Yeh TS, Lee WC, Yeh CT. Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma. PLoS One 2013; 8: e64891. [PMID: 23805180 DOI: 10.1371/journal.pone.0064891]
85. Chung HT, Lai CL, Wu PC, Lok AS. Synergism of chronic alcoholism and hepatitis B infection in liver disease. J Gastroenterol Hepatol 1989; 4: 11-16. [PMID: 2490936 DOI: 10.1111/ j.1440-1746.1989.tb00801.x]
86. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012; 32: 231-240. [PMID: 21745272 DOI: 10.1111/j.1478-3231.2011.02481.x]
87. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011; 54: 434-442. [PMID: 21374690 DOI: 10.1002/hep.24257]
88. Chemin I, Trépo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34 Suppl 1: S15-S21. [PMID: 16461218 DOI: 10.1016/S1386-6532(05)80005-8]
89. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-1089. [PMID: 12360470 DOI: 10.1053/ gast.2002.36026]
90. Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 2009; 101: 1019-1027. [PMID: 19535774 DOI: 10.1093/jnci/djp146]
91. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135. [PMID: 23344543 DOI: 10.1038/nrc3449]
92. Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4853-4857. [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853]
93. Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol 2012; 2: 467-473. [PMID: 22722078 DOI: 10.1016/j.coviro.2012.05.008]
94. Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, Lagorce D, Okanoue T, Urashima T, Bréchot C, PaterliniBréchot P. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 2001; 20: 6233-6240. [PMID: 11593432 DOI: 10.1038/ sj.onc.1204835]
95. Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, Gerin JL. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989; 9: 461-470. [PMID: 2465987 DOI: 10.1002/hep.1840090321]
96. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith P, Trelegan CL. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999; 29: 928-938. [PMID: 10051500 DOI: 10.1002/ hep.510290329]
97. Transy C, Fourel G, Robinson WS, Tiollais P, Marion PL, Buendia MA. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc Natl Acad Sci U S A 1992; 89: 3874-3878. [PMID: 1570307 DOI: 10.1073/pnas.89.9.3874]
98. Marion PI. Molecular Biology of Hepatitis B Virus. Boca Raton, FL: CRC Press, 1991
99. Corradini E, Ferrara F, Pollicino T, Vegetti A, Abbati GL, Losi L, Raimondo G, Pietrangelo A. Disease progression and liver cancer in the ferroportin disease. Gut 2007; 56: 1030-1032. [PMID: 17566043 DOI: 10.1136/gut.2007.122549]
100. Pollicino T, Vegetti A, Saitta C, Ferrara F, Corradini E, Raffa G, Pietrangelo A, Raimondo G. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. J Hepatol 2013; 58: 190-193. [PMID: 22989571 DOI: 10.1016/ j.jhep.2012.09.005]
101. Pontisso P, Morsica G, Ruvoletto MG, Barzon M, Perilongo G, Basso G, Cecchetto G, Chemello L, Alberti A. Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Analysis by polymerase chain reaction. Cancer 1992; 69: 2731-2735. [PMID: 1315210 DOI: 10.1002/1097-0142(19920601)69]
102. Tamori A, Nishiguchi S, Kubo S, Koh N, Moriyama Y, Fujimoto S, Takeda T, Shiomi S, Hirohashi K, Kinoshita H, Otani S, Kuroki T. Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Hepatology 1999; 29: 1429-1434. [PMID: 10216126 DOI: 10.1002/hep.510290520]
103. Bréchot C, Hadchouel M, Scotto J, Fonck M, Potet F, Vyas GN, Tiollais P. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A 1981; 78: 3906-3910. [PMID: 6267609 DOI: 10.1073/pnas.78.6.3906]
104. Paterlini P, Gerken G, Nakajima E, Terre S, D'Errico A, Grigioni W, Nalpas B, Franco D, Wands J, Kew M. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 1990; 323: 80-85. [PMID: 2359427 DOI: 10.1056/NEJM199007123230202]
105. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D, Raimondo G. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-1330. [PMID: 16453330 DOI: 10.1002/cncr.21702]
106. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146: 649-656. [PMID: 17470833 DOI: 10.7326/0003-4819-146-9-2007 05010-00008]
107. Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T, Saigenji K. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res 2008; 38: 546-556. [PMID: 18179561 DOI: 10.1111/j.1872-034X.2007.00316.x]
108. Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, Shiraha H, Koide N. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology 2008; 51: 59-68. [PMID: 18349544 DOI: 10.1159/000121363]
109. Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S, Arakawa Y, Yamagami H, Tanaka N, Moriyama M. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008; 51: 352-361. [PMID: 19127078 DOI: 10.1159/000187720]
110. Kew MC, Welschinger R, Viana R. Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: 1426-1430. [PMID: 18853999 DOI: 10.1111/j.1440-1746.2008.05481.x]
111. Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16: 437-443. [PMID: 19226331 DOI: 10.1111/j.1365-2893.2009.01085.x]
112. Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009; 125: 621-629. [PMID: 19431214 DOI: 10.1002/ ijc.24416]
113. Tamori A, Hayashi T, Shinzaki M, Kobayashi S, Iwai S, Enomoto M, Morikawa H, Sakaguchi H, Shiomi S, Takemura S, Kubo S, Kawada N. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol 2009; 81: 1009-1014. [PMID: 19382258 DOI: 10.1002/jmv.21488]
114. Kondo R, Nakashima O, Sata M, Imazeki F, Yokosuka O, Tanikawa K, Kage M, Yano H; The Liver Cancer Study Group of Kyushu. Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody. Hepatol Res 2013; Epub ahead of print. [PMID: 23937266 DOI: 10.1111/hepr.12219]